<div>A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2</div><div>Inhibitor ABBV-453 given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma</div><div><br /></div>

Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)

Plasmozytom (Multiples Myelom)

BCL (B-cell lymphoma)

BCL-2

Translokation

t(11;14)

Phase I/II

Multiple Myeloma: Evaluate the Safety and Efficacy of ABBV-453 in Monotherapy or in Combination with Antimyeloma Regimens

> Drittlinie

Comprehensive Cancer Center Mainfranken

Studien des CCC Mainfranken